FDA Approves Tafasitamab-cxix for Relapsed or Refractory Follicular Lymphoma By Ogkologos - August 14, 2025 463 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the inMIND study Source RELATED ARTICLESMORE FROM AUTHOR Noninferiority of OS with 3 Months Compared to 6 Months of Adjuvant Chemotherapy for Patients with High-Risk Stage III Colorectal Cancer Patient Guide on Bone Health in Cancer Now Available Also in French Lung Cancer Death Rates Among Women in Europe Are Finally Levelling Off MOST POPULAR Efficacy and Safety of Futibatinib in Patients with Previously Treated Intrahepatic... January 24, 2023 “Your Stories” Podcast: Amplifying Patient Voices September 8, 2020 Young Mom Of Two Survived Breast Cancer, Heart Failure, And Two... January 16, 2020 Educators Raise Money in Memory of Teacher Who Dedicated Herself to... January 19, 2021 Load more HOT NEWS Honeybee Venom May Be the Next Treatment for Aggressive Breast Cancer Pembrolizumab Provides First-Ever Overall Survival Improvement in Kidney Cancer Treating the Whole Person: How Cancer Centers Are Addressing Social Needs “Giving something back”: our supporters are the beating heart of what...
